The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Open accessAbstract
BACKGROUND. Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-γ transcriptional signature in cytotoxic T lymphocytes (CTLs) in human and mouse AA skin and showed that treatment with JAK inhibitors induced durable hair regrowth in mice by targeting this pathway. Here, we investigated the use of the oral JAK1/2 inhibitor ruxolitinib in the treatment of patients with moderate-to-severe AA. METHODS. We initiated an open-label clinical trial of 12 patients with moderate-to-severe AA, using oral ruxolitinib, 20 mg twice per day, for 3–6 months of treatment followed by 3 months follow-up off drug. The primary endpoint was the proportion of subjects with 50% or greater hair regrowth from baseline to end of treatment. RESULTS. Nine of twelve patients (75%) demonstrated a remarkable response to treatment, with average hair regrowth of 92% at the end of treatment. Safety parameters remained largely within normal limits, and no serious adverse effects were reported. Gene expression profiling revealed treatment-related downregulation of inflammatory markers, including signatures for CTLs and IFN response genes and upregulation of hair-specific markers. CONCLUSION. In this pilot study, 9 of 12 patients (75%) treated with ruxolitinib showed significant scalp hair regrowth and improvement of AA. Larger randomized controlled trials are needed to further assess the safety and efficacy of ruxolitinib in the treatment of AA. TRIAL REGISTRATION. Clinicaltrials.gov NCT01950780. FUNDING. Locks of Love Foundation, the Alopecia Areata Initiative, NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the Irving Institute for Clinical and Translational Research/Columbia University Medical Center Clinical and Translational Science Award (CUMC CTSA).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Xing, L., Dai, Z., Jabbari, A., Cerise, J. E., Higgins, C. A., Gong, W., de Jong, A., Harel, S., DeStefano, G. M., Rothman, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3645 · Cited by 987
Self-citationGenome-wide association study in alopecia areata implicates both innate and adaptive immunity
Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., Shimomura, Y., Kim, H., Singh, P., Lee, A., Chen, W. V., et al. (2010) · Nature · doi:10.1038/nature09114 · Cited by 830
Self-citationAlopecia areata investigational assessment guidelines–Part II
Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., Duvic, M., King, L. E., McMichael, A. J., Randall, V. A., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.09.032 · Cited by 798
Bickers (2006) · doi:10.1016/j.jaad.2006.05.048 · Cited by 741
Incidence of Alopecia Areata in Olmsted County, Minnesota, 1975 Through 1989
Safavi, K. H., Muller, S. A., Suman, V. J., Moshell, A. N., & Melton, L. J. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.7.628 · Cited by 528
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89776 · Cited by 355
Self-citationPapp, K. A., Menter, A., Strober, B., Langley, R. G., Buonanno, M., Wolk, R., Gupta, P., Krishnaswami, S., Tan, H., & Harness, J. A. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11168.x · Cited by 338
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115840 · Cited by 334
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Anzengruber, F., Maul, J.-T., Kamarachev, J., Trüeb, R. M., French, L. E., & Navarini, A. A. (2016) · Case Reports in Dermatology · doi:10.1159/000445182 · Cited by 304
Cited by
Pratt, C. H., King, L. E., Messenger, A. G., Christiano, A. M., & Sundberg, J. P. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.11 · Cited by 787
Self-citationJAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Two Phase 3 Trials of Baricitinib for Alopecia Areata
King, B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N. A., Hordinsky, M., Dutronc, Y., Wu, W.-S., McCollam, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2110343 · Cited by 506
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Zhou, C., Li, X., Wang, C., & Zhang, J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08883-0 · Cited by 393
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89776 · Cited by 355
Self-citation
Metadata
- Authors
- Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R.
- Venue
- JCI Insight
- Published
- 2016-09-22
- Volume
- 1
- Issue
- 15
- Pages
- e89790-e89790
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2521310721
- Cited by
- 297
- References
- 22
- FWCI
- 45.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. https://app.cochat.ai/papers/10.1172/jci.insight.89790
- The paper
- Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016). Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. https://doi.org/10.1172/jci.insight.89790
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.